Literature DB >> 7670475

Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds.

N A Gruis1, P A van der Velden, L A Sandkuijl, D E Prins, J Weaver-Feldhaus, A Kamb, W Bergman, R R Frants.   

Abstract

The p16 gene (CDKN2) which is localized on chromosome 9p21, is deleted in a significant number of sporadic cancers. Moreover, germline mutations identified in some melanoma-prone kindreds last year suggested that CDKN2 is identical to the 9p21-linked melanoma susceptibility gene (MLM); however, failure to identify p16 mutations in all melanoma kindreds putatively linked to 9p21 left some doubts. We have analysed CDKN2 coding sequences in 15 Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome pedigrees, and identified a 19 basepair (bp) germline deletion in 13 of them. All 13 families originate from an endogamous population. The deletion causes a reading frame shift, predicted to result in a severely truncated p16 protein. Interestingly, two family members are homozygous for the deletion, one of whom shows no obvious signs of disease. This surprising finding demonstrates that homozygotes for this CDKN2 mutation are viable, and suggests the presence of a genetic mechanism that can compensate for the functional loss of p16. Our results also greatly strengthen the notion that p16 is indeed MLM.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7670475     DOI: 10.1038/ng0795-351

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  66 in total

1.  A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families.

Authors:  P Ciotti; J P Struewing; M Mantelli; A Chompret; M F Avril; P L Santi; M A Tucker; G Bianchi-Scarrà; B Bressac-de Paillerets; A M Goldstein
Journal:  Am J Hum Genet       Date:  2000-06-22       Impact factor: 11.025

2.  Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma.

Authors:  P A van der Velden; L A Sandkuijl; W Bergman; S Pavel; L van Mourik; R R Frants; N A Gruis
Journal:  Am J Hum Genet       Date:  2001-08-07       Impact factor: 11.025

Review 3.  Update on familial pancreatic cancer.

Authors:  H T Lynch; R E Brand; C A Deters; R M Fusaro
Journal:  Curr Gastroenterol Rep       Date:  2001-04

Review 4.  The CDKN2A (p16) gene and human cancer.

Authors:  W D Foulkes; T Y Flanders; P M Pollock; N K Hayward
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

5.  Hereditary p16-Leiden mutation in a patient with multiple head and neck tumors.

Authors:  Regine Schneider-Stock; Anja Giers; Christiane Motsch; Carsten Boltze; Matthias Evert; Bernd Freigang; Albert Roessner
Journal:  Am J Hum Genet       Date:  2003-01       Impact factor: 11.025

6.  Localization of a novel melanoma susceptibility locus to 1p22.

Authors:  Elizabeth Gillanders; Suh-Hang Hank Juo; Elizabeth A Holland; MaryPat Jones; Derek Nancarrow; Diana Freas-Lutz; Raman Sood; Naeun Park; Mezbah Faruque; Carol Markey; Richard F Kefford; Jane Palmer; Wilma Bergman; D Timothy Bishop; Margaret A Tucker; Brigitte Bressac-de Paillerets; Johan Hansson; Mitchell Stark; Nelleke Gruis; Julia Newton Bishop; Alisa M Goldstein; Joan E Bailey-Wilson; Graham J Mann; Nicholas Hayward; Jeffrey Trent
Journal:  Am J Hum Genet       Date:  2003-07-03       Impact factor: 11.025

Review 7.  The essence of senescence.

Authors:  Thomas Kuilman; Chrysiis Michaloglou; Wolter J Mooi; Daniel S Peeper
Journal:  Genes Dev       Date:  2010-11-15       Impact factor: 11.361

8.  P16 deletion and mutation analysis in human brain tumors.

Authors:  F G Barker; P Chen; F Furman; K D Aldape; M S Edwards; M A Israel
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

Review 9.  Germline mutations predisposing to melanoma.

Authors:  Atrin Toussi; Nicole Mans; Jeanna Welborn; Maija Kiuru
Journal:  J Cutan Pathol       Date:  2020-05-11       Impact factor: 1.587

Review 10.  Translating insights from the cancer genome into clinical practice.

Authors:  Lynda Chin; Joe W Gray
Journal:  Nature       Date:  2008-04-03       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.